The Cancer Staging Manual of the American Joint Committee on Cancer (AJCC) has recently been revised and updated to its eighth edition. This review focuses on the new staging system of bone and soft tissue sarcomas and outlines the revision points and caveats in the latest edition. The major changes in the eighth edition of the AJCC staging for bone and soft tissue sarcomas are the following four points. (i) Tumors are described separately according to the primary sites. For bone sarcoma, three tumor locations are described: (a) appendicular skeleton, trunk, skull and facial bones; (b) spine and (c) pelvis. Meanwhile, four tumor locations are described for soft tissue sarcoma: (1) trunk and extremity; (2) retroperitoneum; (3) head and neck and (4) visceral sites.
Introduction
Bone and soft tissue sarcomas are rare malignant tumors accounting for only~1.2% of all malignancies (1) . According to the Bone and Soft Tissue Tumor Registry reported by the Musculoskeletal Tumor Committee of the Japanese Orthopaedic Association, 670 and 1529 patients with bone and soft tissue sarcomas, respectively, were diagnosed in 2015 in Japan (2, 3) .
The Cancer Staging Manual of the American Joint Committee on Cancer (AJCC) has recently been revised and updated to its eighth edition (4) . This review focuses on the new staging system of bone and soft tissue sarcomas and outlines the revision points and caveats in the latest edition.
A major characteristic of TNM classification in bone and soft tissue sarcomas is that histopathologic grade (G) is included as a factor in staging. By contrast, in the TNM system for other cancers, the stage is basically determined by only three factors: T factor based on the depth of tumor infiltration and the greatest diameter of the tumor, N factor of lymph node metastasis and M factor of distant metastasis. In the World Health Organization classification (5), the histologic types of bone and soft tissue sarcomas vary considerably, and the biological properties of individual tumor also differ. Therefore, it is difficult to reflect the prognosis with only three factors of TNM in all tissue types of sarcomas. However, even if the tissue type is different, the biological property could similar if the pathologic grade of the sarcoma is the same. Therefore, with the G factor, a simple staging classification becomes possible for the various tissue types of sarcomas. In addition, because lymph node metastasis is extremely rare in bone soft tissue sarcomas and the N factor is rarely used, if the G factor is not considered, the stage would be determined by only two factors, i.e., T and M. As such, in addition to the usual three TNM factors, the staging system for bone and soft tissue sarcomas includes the factor of histological grade. This point is also followed in this revision.
The major changes in the eighth edition of AJCC staging for bone and soft tissue sarcomas are the following four points.
• In the TNM classification up to the seventh edition (6), the same staging had been used regardless of the primary site of bone and soft tissue sarcomas. However, in the eighth edition, tumors are described separately according to the primary sites mainly due to the differences in the prognosis and treatment strategy. For bone sarcoma, three tumor locations are described: (i) appendicular skeleton, trunk, skull and facial bones; (ii) spine and (iii) pelvis. Meanwhile, four tumor locations are described for soft tissue sarcoma: (i) extremity and trunk; (ii) retroperitoneum; (iii) head and neck and (iv) visceral sites.
• Regarding histologic grade in bone sarcoma, the seventh edition adopted a four-grade classification (grades 1-4), where grades 1 and 2 were assessed as low grade, and grades 3 and 4 were high grade (6) . In the eighth edition, however, three-grade classifications are recommended for both bone and soft tissue tumors to avoid confusion, in which grade 1 is considered as low grade and grades 2 and 3 are high grade.
• In the treatment of lymph node metastasis of soft tissue tumors, anyTN1M0 was included in stage IIIB in the seventh edition (6) . In the eighth edition, anyTN1M0 for the tumor in the trunk and extremity is classified as stage IV probably because the prognosis of anyTN1M0 was rather close to that of anyTN0M1 than anyTN0M0. However, this change is only for the trunk and extremity, and anyTN1M0 remains stage IIIB for retroperitoneal tumors.
• Regarding the T factor of soft tissue sarcoma in the seventh edition, the tumor size was classified into two categories of ≤5 cm or >5 cm (6). In the eighth edition, tumor size for the trunk and extremity and retroperitoneal soft tissue sarcomas was classified into four categories based on the difference in prognosis: (i) ≤5 cm, (ii) > 5 cm and ≤10 cm, (iii) > 10 cm and ≤15 cm and (iv) > 15 cm. In addition, the notation about the depth of the tumor (superficial or deep from the superficial fascia) has been eliminated.
Bone sarcoma
The new staging is applied for all primary bone sarcomas, except primary malignant lymphoma and multiple myeloma of bone. The classification system of the eighth edition is the same as that of the seventh edition except that the histologic grade is changed from the conventional four-grading system to a three-grading system as in for soft tissue sarcoma.
In the TNM classification for bone sarcomas arising in the appendicular skeleton, trunk, skull and facial bones, a tumor is first divided into stage I (grade 1) and stage II or more (grade 2 or 3) according to the histologic grade. Then the T factor, i.e., tumor size (T1, ≤8 cm; T2, >8 cm; T3, discontinuous tumors in the primary bone site), determines the stage. Reginal lymph node metastasis (N1) and distant organ metastasis (M1a, lung; M1b, bone or other distant sites) are assessed as stage IV regardless of histologic grade or tumor size. However, because lymph node metastasis or extrapulmonary metastasis including bone (M1b) has a poorer prognosis than lung metastasis, lung metastasis (M1a) is classified as stage IVA and regional lymph node metastasis or extrapulmonary metastasis as stage IVB (Table 1) .
For spine and pelvic bone sarcomas, T factor is newly described in the eighth edition with a different criterion from that of appendicular skeleton as described below. However, the staging of bone sarcomas occurring in the spine and pelvic bone is not defined.
A) Appendicular skeleton, trunk, skull and facial bones (4)
Definition of primary tumor (T) IA  T1  N0  M0  G1 or GX  IB  T2 or T3  N0  M0  G1 or GX  IIA  T1  N0  M0  G2 or G3  IIB  T2  N0  M0  G2 or G3  III  T3  N0  M0  G2 or 
Extension of gross vascular invasion or tumor thrombus in the great vessels
C) Pelvis (4)
Definition of primary tumor (T)
T Category T Criteria TX Primary tumor cannot be assessed T0
No evidence of primary tumor T1 Tumor confined to one pelvic segment with no extraosseous extension T1a
Tumor ≤8 cm in greatest dimension T1b
Tumor >8 cm in greatest dimension T2 Tumor confined to one pelvic segment with extraosseous extension or two segments without extraosseous extension T2a
Tumor ≤8 cm in greatest dimension T2b
Tumor >8 cm in greatest dimension T3
Tumor spanning two pelvic segments with extraosseous extension T3a
Tumor ≤8 cm in greatest dimension T3b
Tumor >8 cm in greatest dimension T4
Tumor spanning three pelvic segments or crossing the sacroiliac joint T4a
Tumor involves sacroiliac joint and extends medial to the sacral neuroforamen T4b
Tumor encasement of external iliac vessels or presence of gross tumor thrombus in major pelvic vessels
Soft tissue sarcoma
For soft tissue sarcomas, the descriptions that differ in stage classification depending on the site of primary tumor have been made from the eighth edition. Staging should be done with careful attentions because there are tissue types excluded in each location of the tumor. The histologic types that require these special considerations are summarized in a separate chapter as 'Soft Tissue SarcomaUnusual Histologies and Sites'. Gastrointestinal stromal tumor is described as a soft tissue sarcoma in the eighth edition; however, it is omitted in this review. A tumor is first divided into stage I (low grade: grade 1) and stage II or more (high grade: grade 2 or 3) according to the histologic grade in TNM classification of soft tissue sarcomas. Then, T factor according to the tumor size determines the stage.
The notation on the depth of the primary soft tissue tumor (superficial or deep from the superficial fascia) that had been considered in the staging in the seventh edition has been eliminated and excluded as a factor of staging in the eighth edition. In addition, lymph node metastasis and distant organ metastasis are now considered stage IV disease regardless of tumor histology or size ( Table 2) .
The biggest change in the revision from the sixth edition to the seventh edition was that a tumor with regional lymph node metastasis without distant metastasis, i.e., anyTN1M0anyG, was defined as stage IV in the sixth edition (7) but as stage IIIB in the seventh edition (6) . In the eighth edition, anyTN1M0anyG tumor is reverted to stage IV as in the sixth edition for soft tissue sarcomas in the trunk and extremity. Meanwhile, in the eighth edition of the Union for International Cancer Control (UICC) TNM classification, anyTN1M0anyG tumor is classified as stage IIIB (8); this discrepancy should be given attention.
Regarding soft tissue sarcoma in the retroperitoneum, the staging system both of AJCC and UICC is the same: anyTN1M0anyG remains as stage IIIB as in the seventh edition. Other stage classifications for retroperitoneum sarcoma are also the same as those for the trunk and extremity (Table 3) .
For evaluation of histologic grade in soft tissue sarcoma, the Fédération Nationale des Centers de Lutte Contre Cancer (FNCLCC) system is recommended (9) . In this system, the histologic grade is classified into three (grades 1, 2 and 3) according to the total of the scores of tissue type (degree of tumor differentiation), extent of necrosis and mitotic counts. Grade 1 corresponds to low grade, while grades 2 and 3 correspond to high grade.
Regarding the newly described soft tissue sarcoma of the 'head and neck' and the 'abdomen and thoracic visceral organs' in the eighth edition, each T factor has different criteria as shown in the following. However, the prognostic stage groups of soft tissue sarcomas in these sites are not defined. Table 2 . AJCC prognostic stage groups for soft tissue sarcoma in the trunk and extremity
Stage
Primary tumor (T) Regional lymph node (N) Distant metastasis (M) Histologic grade (G)   IA  T1  N0  M0  G1, GX  IB  T2, T3, T4  N0  M0  G1, GX  II  T1  N0  M0  G2, G3  IIIA  T2  N0  M0  G2, G3  IIIB  T3, T4  N0  M0  G2, G3  IV  Any T  N1 
Conclusion
In the eighth edition, bone sarcomas and soft tissue sarcomas are described according to primary tumor site for the first time. The specific criteria depending on tumor site is made for T factor. Some improvements are also noted, such as the histologic grades of both bone and soft tissue sarcomas becoming a three-grade classification. However, several problems remain, including (i) AnyTN1M0 is differently classified by site of soft tissue sarcoma as stage IIIB or stage IV and (ii) there are many sites where T factors are defined but stages are not stipulated. Data should be continually accumulated based on the new TNM staging, and more improvements can be expected at the next revision.
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